Skip to main content

Table 1 Alterations in oncogenes or tumor suppressor genes (TSGs) identified in the primary tumor (P1) and lung metastasis (M1) of Patient 1 or the primary tumor (P2) and recurrence (R2) of Patient 2. Variants of unknown significance (VUS) were assigned according to the FoundationOne® (CDx) report

From: Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers

Gene

Oncogene

TSG

Type of alteration

Patient

Prediction of functional consequences

Occurrence of genomic alterations previously reported in phyllodes tumors

General classification

Details

VUS

1

2

FATHMM-XF

Mutation Taster2

Specific alteration

Other alterations

Type of tissue

APC

 

+

non-syn. SNV

p.R230H

+

P1, M1

 

0.98, pathogenic

Disease causing

NR

NR

 

ARID1A

 

+

non-fs deletion

p.A345_A349del

 

M1

 

Polymorphisma

NR

One case, non-syn. SNV [18]

P

benign

   

non-fs insertion

p.A247_G248insA

+

 

P2, R2

Polymorphism

NR

  

BCOR

 

+

splicing, stop gain

p.R1031fs*23

  

P2

Disease causing

NR

Few cases [13, 38]

P borderline,

malignant

BRIP1

 

+

non-syn. SNV

p.M1V

 

P1, M1

 

0.02, benign

Polymorphism

NR

NR

 

CARD11

+

 

non-syn. SNV

p.S925C

+

 

P2, R2

NA

Polymorphism

NR

Few cases: amplification [14, 16]

P

malignant

CASP8

 

+

non-syn. SNV

p.F18L

+

P1

 

NA

Polymorphism

NR

NR

 

CDK4

+

 

non-syn. SNV

p.T102K

+

P1, M1

 

NA

Disease causing

NR

NR

 

EGFR

+

 

non-syn. SNV

p.Q432K

  

P2

0.71, pathogenic

Disease causing

NR

Several non-syn. SNVs [12, 13, 16, 18]

P

malignant

   

amplification

copy no. = 11

  

R2

Several cases

[9, 11,12,13,14, 18]

 

P, M

malignant

GRIN2A

+

+

non-syn. SNV

p.T141K

+

M1

 

NA

Polymorphism

NR

NR

 

IGF1R

+

 

amplification

copy no. = 6

  

P2

Two cases [11]

 

P

malignant

    

copy no. = 19

  

R2

   

KIT

+

 

amplification

copy no. = 21

  

P2

One case [13]

NR

P

malignant

    

copy no. = 27

  

R2

   

MED12

+

 

non-syn. SNV

p.G44V

 

P1, M1

 

0.95, pathogenic

Disease causing

Hotspot [9, 11, 13, 14, 18]

High frequency [9, 11, 13, 14, 16, 18]

P, R, M

all grades

KMT2D

(MLL2)

 

+

fs deletion, stop gain

p.E2603fs*88

 

P1, M1

 

Disease causing

NR

Several cases [9, 13, 16, 38]

P, M

all grades

   

stop gain

p.Q3293*

   

NA

Disease causing

NR

Stop gain [13, 14, 16, 18]

 

MYC

+

 

amplification

copy no. = 33

  

P2

Several cases [10, 11, 13, 18]

NR

P

malignant

    

copy no. = 44

  

R2

   

PAX5

+

+

non-syn. SNV

p.S213L

+

 

P2, R2

0.89, pathogenic

Disease causing

NR

One case [38]

P, benign

PDGFRA

+

 

amplification

copy no. = 24

  

P2

few cases [11, 13]

NR

R

malignant

   

amplification

copy no. = 35

  

R2

   

RB1

 

+

fs deletion, stop gain

I124fs*6

  

P2

Disease causing

NR

Several cases

[9,10,11,12,13,14, 16, 18]

P, M

borderline malignant

   

stop gain

p. Y321*

  

P2

NA

Disease causing

   

TERT

+

+

promoter

c.-124C > T

 

P1, M1

 

NA

NA

Hotspot

  

[9, 13,14,15, 18]

high frequency [9, 14,15,16, 18]

P, R

all grades

          

TP53

 

+

non-syn. SNV

p.R249S

 

P1, M1

 

NA

Disease causing

NR, c.747G > C

High frequency [9, 11,12,13,14, 16, 18]

P, R, M

mostly malignant

   

non-syn. SNV

G262V

  

P2, R2

1.00, pathogenic

Disease causing

NR

  
   

non-syn. mutation

p.Q_S6 > HP

  

R2

Polymorphism

NR

  
   

deletion

exons 2–9

  

P2, R2

NR

Deletion of gene [10]

P, distant malignant

  1. apolymorphism is probably harmless, according to the definition of MutationTaster2[23]
  2. fs, frameshift; M, distant metastases; NA, not available; NR, not reported; P, primary tumor; R, recurrence; non-syn. SNV, non-synonymous single-nucleotide variant; VUS, variants of unknown significance; *, stop codon